5-(3'-thienylidene)-2,4-dioxotetrahydro-1,3-thiazole | 139336-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-(3'-thienylidene)-2,4-dioxotetrahydro-1,3-thiazole
• 英文别名: (5Z)-5-(thiophen-3-ylmethylidene)-1,3-thiazolidine-2,4-dione
• CAS: 139336-29-1
• 化学式: C₈H₅NO₂S₂
• 分子量: 211.265
• InChiKey: YIBJLSACWOVLEB-UTCJRWHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3'-thienylidene)-2,4-dioxotetrahydro-1,3-thiazole 生成 potassium;(5Z)-5-(thiophen-3-ylmethylidene)-1,3-thiazolidin-3-ide-2,4-dione
  参考文献：
  名称：

  POPOV-PERGAL, KATARINA;CEKOVIC, ZIVORAD;PERGAL, MIROSLAV, J. SERB. CHEM. SOC., 55,(1990) N, C. 495-500

  摘要：

  DOI：
• 作为产物：
  描述：

  3-噻吩甲醛 、 2,4-噻唑烷二酮 在 吗啉 、 溶剂黄146 作用下， 以 苯 为溶剂， 以54.5%的产率得到5-(3'-thienylidene)-2,4-dioxotetrahydro-1,3-thiazole
  参考文献：
  名称：

  Popov-Pergal, K.; Cekovic, Z.; Pergal, M., Journal of general chemistry of the USSR, 1991, vol. 61, # 9.2, p. 1958 - 1962

  摘要：

  DOI：

文献信息

• PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME
  申请人：Yonsei University, University-Industry Foundation(UIF).

  公开号：EP4083037A1

  公开（公告）日：2022-11-02

  Provided are: a novel pyrrolidine derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same and having the effects of inhibiting beta-amyloid and/or tau protein aggregation, and/or breaking down beta-amyloid and/or tau protein aggregates, and/or preventing and/or treating beta-amyloid and/or tau protein-associated diseases.

  本文提供了：一种新型吡咯烷衍生物或其药学上可接受的盐；以及一种含有该衍生物并具有抑制β-淀粉样蛋白和/或tau蛋白聚集和/或分解β-淀粉样蛋白和/或tau蛋白聚集和/或预防和/或治疗β-淀粉样蛋白和/或tau蛋白相关疾病的作用的药物组合物。
• Popov-Pergal, K.; Cekovic, Z.; Pergal, M., Journal of general chemistry of the USSR, 1991, vol. 61, # 9.2, p. 1958 - 1962
  作者：Popov-Pergal, K.、Cekovic, Z.、Pergal, M.

  DOI：——

  日期：——
• POPOV-PERGAL, KATARINA;CEKOVIC, ZIVORAD;PERGAL, MIROSLAV, J. SERB. CHEM. SOC., 55,(1990) N, C. 495-500
  作者：POPOV-PERGAL, KATARINA、CEKOVIC, ZIVORAD、PERGAL, MIROSLAV

  DOI：——

  日期：——
• [EN] THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS<br/>[FR] DERIVES DE THIAZOLIDINE UTILES POUR LE TRAITEMENT ET LA PREVENTION DE TROUBLES METABOLIQUES DES OS
  申请人：ROCHE DIAGNOSTICS GMBH

  公开号：WO2000018746A1

  公开（公告）日：2000-04-06

  The object of the present invention are compounds of general formula (I), in which: m signifies a number between 0-8; q signifies a number between 0-8; A signifies a single or double bond; R1 signifies hydrogen or, when X and Z are oxygen, also -(CH2)-COR4 with a =0-6; R2, R3 signify hydrogen or lower alkyl, whereby R2 and R3 can be the same or different and, when m signifies 2-8, R2 and R3 in the group CR2=CR3 can have various significances within the following sequence; R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 can be the same or different; X signifies oxygen or imino; Z signifies oxygen, sulfur or imino; W signifies an optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricycle which can contain one or more hetero atoms, as well as their physiologically compatible salts, esters, optically active forms, racemates, tautomers, as well as derivatives which can be metabolized in vivo to compounds of general formula (I), as well as the use of these compounds for the production of medicaments for the prophylaxis or therapy of metabolic bone disorders.
• [EN] PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME<br/>[FR] DÉRIVÉ DE PYRROLIDINE ET COMPOSITION PHARMACEUTIQUE DE PRÉVENTION OU DE TRAITEMENT DE MALADIES ASSOCIÉES À LA PROTÉINE BÊTA-AMYLOÏDE OU TAU CONTENANT CE DERNIER<br/>[KO] 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
  申请人：YONSEI UNIV UNIV INDUSTRY FOUNDATION UIF

  公开号：WO2021133037A1

  公开（公告）日：2021-07-01

  신규한 피롤리딘 유도체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 베타-아밀로이드 및/또는 타우 단백질의 응집 억제 및/또는 베타-아밀로이드 및/또는 타우 단백질의 응집체 분해, 및/또는 베타-아밀로이드 및/또는 타우 단백질 관련 질병의 예방 및/또는 치료 효과를 갖는 약학 조성물이 제공된다.